Core Insights - Bio-Techne Corporation has launched its next-generation Leo System, which utilizes Simple Western Technology to enhance life science research capabilities [1][4] Product Features - The new Leo System incorporates dual-channel fluorescence detection alongside chemiluminescence, increasing data throughput and efficiency while providing deeper insights from samples [2] - It offers a fourth multiplexing option, allowing researchers to quantify targets with varying expression levels and assess different proteoforms in the same capillary, processing up to 100 capillaries in three hours [2][6] Performance and Precision - The Leo System is noted for its high-throughput capabilities, achieving a variability of only 5-6%, which is considered remarkable in clinical research [3] - The system is designed to deliver unmatched precision and efficiency in protein analysis, enabling faster and more reliable results [4] Market Position - Bio-Techne aims to strengthen its leadership in proteomic analytical instruments with the Leo System, which supports complex assay configurations and compliance with regulatory standards [6] Company Overview - Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people globally, providing innovative tools and reagents for research and clinical diagnostics [5]

Core Insights - Bio-Techne Corporation's Simple Western™ Technology was instrumental in the FDA approval of ZEVASKYN™, the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) developed by Abeona Therapeutics [1][5] - ZEVASKYN addresses a significant unmet medical need for RDEB patients, who previously had no durable therapies available [3][8] Company Overview - Bio-Techne Corporation is a global life sciences company that generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide [6] - Abeona Therapeutics is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases, with ZEVASKYN being its flagship product [8] Technology and Methodology - Simple Western was chosen by Abeona for its speed, reproducibility, sensitivity at picogram levels, and minimal sample volume requirements, effectively detecting both trimeric and monomeric forms of Collagen VII [2][4] - The platform provided GMP-compliant data to ensure consistency across ZEVASKYN product lots, overcoming challenges in analytical standardization and complex assay development [4] Clinical Significance - RDEB is a rare genetic skin disorder caused by mutations in the COL7A1 gene, leading to severe symptoms and increased risk of life-threatening complications [3] - The approval of ZEVASKYN marks a significant milestone in the field of cell-based gene therapy, providing a new treatment option for RDEB patients [5]